Siamo lieti di comunicare che AIFA, ha autorizzato la modifica della posologia di NETILDEX® gel oftalmico con riduzione del numero di somministrazioni giornaliere da 4 a 2.
📌Per saperne di più:
https://t.co/wmRPUDDRfd
#innovation#ophthalmology#cataractsurgery
Sicily-based ophthalmic product specialist SIFI Group has grown since its establishment in 1935.
Last year, they launched Well Fusion, a novel formulation of artificial tears.
To find out below about their innovations, read our itw with Fabrizio Chines.
https://t.co/gQ7SLwCyhX
"Never before has it been so important to remember that scientific progress makes the difference in the for all of us"- Sergio Dompé, TF Chair Healthcare & Life Sciences #B20Italy with @ArmandoTestaSpA#MoreThanScience
SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-ocular in Dry Eye Disease. Trial involves 4 leading ophthalmic centers in Italy & is expected to recruit 105 participants: https://t.co/0jmTmOcGg1 #dryeye#innovation#research#biotech#pharma#Ophthalmology
UPDATE #COVID19
🇮🇹 #Italy report, March 23, 17:00 CET
Confirmed cases: 63927 (+4789 last 24 hrs) ↘️
On intensive care: 3204
Recovered: 7432 (+408 last 24 hrs) ↘️
Deaths: 6077 (+601 last 24 hrs) ↘️
Lowest number new cases since Mar 18
Lowest number new deaths since Mar 19
Proud of this important milestone. Great #teamwork at SIFI and Knight Therapeutics #pharmaceuticals#ophthalmology.
Knight Therapeutics and SIFI S.p.A. Announce Approval of NETILDEX™ in Canada https://t.co/yBMuUM2oNi di @business